HUMAN PARAINFLUENZA VIRUS TYPE 3

Clinical trials for HUMAN PARAINFLUENZA VIRUS TYPE 3 explained in plain language.

Never miss a new study

Get alerted when new HUMAN PARAINFLUENZA VIRUS TYPE 3 trials appear

Sign up with your email to follow new studies for HUMAN PARAINFLUENZA VIRUS TYPE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Nasal spray vaccine shows promise against childhood lung virus

⭐️ VACCINE ⭐️ Completed

This study tested two experimental nasal spray vaccines designed to protect children against human metapneumovirus (HMPV) and parainfluenza virus type 3 (HPIV3), both of which can cause serious breathing problems. Twenty-four children aged 2 to 5 who already had antibodies to HPI…

Matched conditions: HUMAN PARAINFLUENZA VIRUS TYPE 3

Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️

Last updated May 17, 2026 08:04 UTC

HUMAN PARAINFLUENZA VIRUS TYPE 3

Get alerted when new HUMAN PARAINFLUENZA VIRUS TYPE 3 trials appear

Nasal spray vaccine shows promise against childhood lung virus